ECTICA TECHNOLOGIES AG is a young and innovative life science company, dedicated to develop and manufacture next generation discovery tools and technologies for oncology research. Ectica was founded in 2015 as a spin-off company of the University and ETH Zurich (Switzerland). Ectica has developed and marketed a patented hydrogel-based platform (3DProSeedTM) particularly suited to study the functional interactions at a cellular level between cancer cells and the cells of the tumor stromal environment, maintaining the highest level of automation compatibility in screening workflows. Our new 3DProSeed StromaLine evolve to offer our partners and customers an attractive collection of ex-vivo pre-developed and characterized stromal models to study tumor interaction. In collaboration with clinical research partners and biopharma companies, we want to develop advanced predictive functional assays to assess ex vivo efficacy and safety of anti-cancer therapies.
